Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03685123 · ClinicalTrials.gov registry record · NA
Exercise After Clinically Significant Weight Loss
A NA study, sponsored by East Carolina University.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT03685123: Completed NA study, sponsored by East Carolina University.
NCT03685123 is a NA study that has completed, run by East Carolina University. The registered enrollment target is 39 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03685123, a NA study, has completed, sponsored by East Carolina University.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
The Prescribed Exercise to Reduce Recidivism After Weight Loss Pilot (PREVAIL-P) study will evaluate the effect of aerobic exercise training amount on weight maintenance following clinically significant weight loss.
Primary Outcome
Weight will measured in a hospital gown on a balance beam scale. Change in weight will be calculated as the participant weight change from the end of the weight loss phase to the end of the weight maintenance phase (week 28 weight subtracted from the week 10 weight). A positive value indicates an increase in weight and a negative value indicates a reduction in weight
Interventions
- BEHAVIORAL Physical activity recommendations
- BEHAVIORAL Weight maintenance recommendations
- BEHAVIORAL OPTIFAST weight loss
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-02-12 |
| Est. Completion | 2020-03-15 |
| Phase | NA |
What the finished NCT03685123 record still lists
NCT03685123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Physical activity recommendations is the first listed.
NCT03685123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03685123 about?
NCT03685123 is a clinical study titled "Exercise After Clinically Significant Weight Loss". The Prescribed Exercise to Reduce Recidivism After Weight Loss Pilot (PREVAIL-P) study will evaluate the effect of aerobic exercise training amount on weight maintenance following clinically significant weight loss.
What is the current status of trial NCT03685123?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2019-02-12. Estimated completion is 2020-03-15.
What interventions are being tested in trial NCT03685123?
The interventions under investigation include: Physical activity recommendations (BEHAVIORAL), Weight maintenance recommendations (BEHAVIORAL), OPTIFAST weight loss (BEHAVIORAL).
Who is sponsoring clinical trial NCT03685123?
This trial is sponsored by East Carolina University, which has 58 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03685123's enrollment target sits among peer trials
39 1536th of 2000 higher than 463 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI